NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-052-2021-0-JP-01 Engineered Influenza Neuraminidase Antigens JP National Stage 2022-554464 Pending
NCI E-031-2020-0-KR-10 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION KR National Stage 10-2022-7031175 Pending
NIAID E-086-2020-0-KR-13 SARS-CoV-2 VACCINE KR National Stage 10-2022-7031250 Pending
NIAID E-185-2022-0-US-01 Engineered SARS-CoV-2 Antibodies With Increased Neutralization Breadth US 63/404,473 Expired
NCI E-074-2020-1-IN-07 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION IN National Stage 202247050807 Pending
NIDDK E-043-2020-0-CA-01 RNA Target Enrichment or Depletion of Biological Samples CA National Stage 3174707 Pending
NIAID E-168-2020-2-KR-01 Corona Virus Binders KR National Stage 10-2022-7030791 Pending
NIDDK E-101-2020-0-US-04 Antibacterial And Antifungal Polyketides From Environmental Amycolatopsis Spp. US National Stage 17/909,051 Pending
NCI E-169-2022-0-US-01 Single Domain Antibodies Targeting HPV E6/E7 Oncogenic Peptide/MHC Complexes US 63/374,307 Expired
NIAID E-052-2021-0-CA-01 Engineered Influenza Neuraminidase Antigens CA National Stage 3170375 Pending
NCI E-234-2014-1-AU-02 METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF AU DIV 2022224780 Issued
NCI E-282-2016-2-AU-01 METHODS OF CONDITIONING PATIENTS FOR T CELL THERAPY AU DIV 2022224754 Pending
NIAID E-183-2022-0-US-01 Multi Protein Nanoparticle Monkeypox Vaccine US 63/402,702 Expired
CC E-180-2022-0-US-01 SYSTEMS OF METHODS FOR DETECTING OMICRON SARS-CoV-2 VARIANTS WITH DEEP LEARNING AND VOICE DATA INPUT US 63/374,214 Expired
NCI E-169-2021-0-PCT-02 MIXED LINEAGE KINASE INHIBITORS AND METHODS OF USE PCT PCT PCT/US2022/075678 Expired
NCI E-105-2019-0-CN-05 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION CN National Stage 202080096478.2 Pending
NCI E-174-2018-2-JP-01 CAS9 Modified TILS For Treatment Of Gastrointestinal Cancer JP DIV 2022-135735 Pending
NCI E-088-2020-0-JP-09 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION JP National Stage 2022-551537 Issued
NCI E-088-2020-0-US-13 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION US National Stage 17/802,464 Pending
NCI E-168-2011-0-US-47 METHODS AND COMPOSITIONS FOR INHIBITING POLYOMAVIRUS-ASSOCIATED PATHOLOGY US DIV 17/822,345 Abandoned
NCI E-088-2020-0-CN-06 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION CN National Stage 202180016761.4 Pending
NEI E-004-2017-0-US-08 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY US DIV 17/894,773 Pending
NHLBI E-090-2020-0-IL-06 NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND USE FOR TREATING CANCER IL National Stage 295888 Pending
NHLBI E-090-2020-0-US-03 NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND
METHODS OF USE 		US CON 17/821,703 Abandoned
NIAID E-240-2023-0-US-02 VACCINES AGAINST CORONAVIRUSES US 63/400,334 Expired
NIAID E-086-2020-0-IN-09 SARS-CoV-2 VACCINE IN National Stage 202217047972 Pending
NCI E-088-2020-0-NZ-16 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION NZ National Stage 791348 Pending
NCI E-088-2020-0-CA-05 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION CA National Stage 3169086 Pending
NCI E-088-2020-0-AU-04 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION AU National Stage 2021225872 Pending
NCI E-088-2020-0-GB-12 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION GB National Stage 2212195.8 Issued
NIAID E-240-2023-0-US-01 VACCINES AGAINST CORONAVIRUSES US 63/399,990 Expired
NCI E-088-2020-0-BR-14 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION BR National Stage BR112022016661-3 Pending
NIAID E-152-2022-0-US-01 HIV-1 IMMUNOGENS AND THEIR USE US 63/399,709 Expired
NIAID E-168-2020-2-CA-01 Corona Virus Binders CA National Stage 3166967 Abandoned
NCI E-042-2014-0-IN-35 Chimeric Antigen Receptors Targeting CD-19 IN DIV 202248047256 Pending
NCI E-088-2020-0-SG-11 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION SG National Stage 11202252357K Pending
NCATS E-168-2019-0-JP-06 RADIAL GLIA AND ASTROCYTE DIFFERENTIATION FROM HUMAN
PLURIPOTENT STEM CELLS 		JP National Stage 2022-549610 Issued
NIAID E-020-2020-0-US-04 EPSTEIN-BARR VIRUS MONOCLONAL ANTIBODIES AND USES THEREOF US National Stage 17/800,706 Pending
NCI E-116-2017-0-US-04 Compositions and Methods for Treating Cancer with Anti-CD33 Immunotherapy US CON 17/820,724 Pending
NEI E-057-2020-0-US-06 Method and Systems for Predicting Rates of Progression of Age-Related Macular Degeneration US National Stage 17/904,573 Pending
NCI E-159-2019-0-EP-05 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) EP National Stage 21705769.4 Pending
NCI E-088-2020-0-MX-15 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION MX National Stage MX/a/2022/010157 Pending
NCI E-159-2019-0-AU-04 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) AU National Stage 2021210915 Pending
NCI E-169-2018-0-EP-05 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE EP National Stage 21705753.8 Pending
NCI E-174-2022-0-US-01 Synergistic Interactions For Improved Cancer Treatment US 63/398,450 Expired
NHLBI E-134-2022-0-US-01 SYSTEMS AND METHODS FOR ELECTROCARDIOGRAPHIC RADIAL DEPTH
NAVIGATION OF INTRACARDIAC DEVICES 		US 63/371,490 Expired
NCI E-171-2018-7-IL-12 MODIFIED CELLS AND METHODS OF THERAPY IL DIV 295616 Abandoned
NCI E-074-2020-1-JP-08 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION JP National Stage 2022-549088 Issued
NCCIH E-081-2020-0-US-02 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN US National Stage 17/799,500 Pending
NCI E-074-2020-1-CN-05 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION CN National Stage 202180014281.4 Pending